FDA
-
-
-
-
-
-
-
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
-
-
-
-
-
-
-
Renalytix Reports Full Year Fiscal 2023 Results
-
-
-
-
-
-
-
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
-
-
-
-
-
-
-
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
-
-
-
-
-
-
-
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
-
-
-
-
-
-
-
Renalytix plc Issue of shares
-
-
-
-
-
-
-
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

